G-CSFR expression in T cells before and after G-CSF treatment in vivo analyzed by single-cell RT-PCR
Timepoint . | CD3+ T cells (%) . | CD4+ T cells (%) . | CD8+ T cells (%) . |
|---|---|---|---|
| Before G-CSF | 0/89 (0) | 0/36 (0) | 0/32 (0) |
| Donor 1 | 0/28 (0) | — | — |
| Donor 2 | 0/21 (0) | — | — |
| Donor 3 | — | 0/16 (0) | 0/16 (0) |
| Donor 4 | — | 0/20 (0) | 0/16 (0) |
| Donor 5 | 0/13 (0) | — | — |
| Donor 6 | 0/15 (0) | — | — |
| Donor 7 | 0/12 (0) | — | — |
| After G-CSF | 36/102 (35) | 22/80 (27) | 33/86 (38) |
| Donor 1 | 14/36 (38.9) | — | — |
| Donor 2 | 6/19 (31.6) | — | — |
| Donor 3 | — | 6/21 (28.6) | 6/16 (37.5) |
| Donor 4 | — | 4/16 (25) | 8/19 (42.1) |
| Donor 5 | 8/16 (50) | 5/15 (33) | 5/20 (25) |
| Donor 6 | 4/16 (25) | 3/14 (21) | 7/16 (43) |
| Donor 7 | 4/15 (27) | 4/14 (28) | 7/15 (46) |
Timepoint . | CD3+ T cells (%) . | CD4+ T cells (%) . | CD8+ T cells (%) . |
|---|---|---|---|
| Before G-CSF | 0/89 (0) | 0/36 (0) | 0/32 (0) |
| Donor 1 | 0/28 (0) | — | — |
| Donor 2 | 0/21 (0) | — | — |
| Donor 3 | — | 0/16 (0) | 0/16 (0) |
| Donor 4 | — | 0/20 (0) | 0/16 (0) |
| Donor 5 | 0/13 (0) | — | — |
| Donor 6 | 0/15 (0) | — | — |
| Donor 7 | 0/12 (0) | — | — |
| After G-CSF | 36/102 (35) | 22/80 (27) | 33/86 (38) |
| Donor 1 | 14/36 (38.9) | — | — |
| Donor 2 | 6/19 (31.6) | — | — |
| Donor 3 | — | 6/21 (28.6) | 6/16 (37.5) |
| Donor 4 | — | 4/16 (25) | 8/19 (42.1) |
| Donor 5 | 8/16 (50) | 5/15 (33) | 5/20 (25) |
| Donor 6 | 4/16 (25) | 3/14 (21) | 7/16 (43) |
| Donor 7 | 4/15 (27) | 4/14 (28) | 7/15 (46) |
T-cell populations were isolated by microbead technology (purity > 98%) and subsequently handpicked. The analyzed single cells could be identified as T cells because of coamplification of the TCR-α chain mRNA. G-CSFR expression was significantly induced upon G-CSF treatment in vivo (P < .01), but did not differ significantly among the analyzed 7 donors (P > .05).—indicates not determined